Company: PSTV
Filing Date: 2025-07-11
Form Type: PRE 14A
Source: 0001140361-25-025650
Chunk: 27

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-11
Form: PRE 14A
Chunk 27
---
    Committee |     | Nominating    
 and Corporate 
 Governance    
 Committee     |
| An van Es-Johansson, M.D. |     |           |     |              |     |               |
| Howard Clowes             |     |           |     |              |     |               |
| Robert Lenk, PhD          |     |           |     |              |     |               |
| Greg Petersen(1)          |     |           |     |              |     |               |
| Total meetings in 2024    |     |         4 |     |            4 |     | 0(2)          |

| Financial Expert |
| Committee Chair  |
| Committee Member |

| (1) | Greg Petersen resigned from the Board and his committee positions on April 18, 2025. Kyle Guse replaced all committee positions previously held by Greg Petersen, including the title of financial expert. |

| (2) | All Nominating and Corporate Governance Committee matters in 2024 were handled through unanimous written consent. |

The Board has determined that each member of each standing committee meets the applicable Nasdaq rules and regulations regarding “independence” and each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to the Company. Each Board member attended 75% or more of the aggregate number of meetings of the standing committee on which she or he served, held during the last fiscal year for which she or he was a committee member.

14

TABLE OF CONTENTS

Below is a description of each committee of our Board. Audit Committee Our Audit Committee currently consists of Mr. Clowes, Dr. van Es-Johansson and Mr. Guse, who serves as Chairperson of the Audit Committee. The Board has determined that all members of the Audit Committee satisfied the independence requirements under Nasdaq listing standards and Rule 10A-3(b)(1) of the Exchange Act. The Board has determined that Mr. Guse is an “audit committee financial expert” within the meaning of SEC regulations. Each member of our Audit Committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, the Board has examined each Audit Committee member’s scope of experience and the nature of their employment. No member of the Audit Committee simultaneously serves on the audit committees of more than three (3) public companies, and no member of our Audit Committee has participated in the preparation of the financial statements of Plus at any time during